116 related articles for article (PubMed ID: 38818978)
1. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
Martino EA; Palmieri S; Galli M; Derudas D; Mina R; Della Pepa R; Zambello R; Vigna E; Bruzzese A; Mangiacavalli S; Zamagni E; Califano C; Musso M; Conticello C; Cerchione C; Mele G; Di Renzo N; Offidani M; Tarantini G; Casaluci GM; Rago A; Ria R; Uccello G; Barilà G; Palumbo G; Pettine L; Vincelli ID; Brunori M; Accardi F; Amico V; Amendola A; Fontana R; Bongarzoni V; Rossini B; Cotzia E; Gozzetti A; Rizzi R; Sgherza N; Reddiconto G; Maroccia A; Franceschini L; Bertuglia G; Nappi D; Barbieri E; Gamberi B; Petrucci MT; Di Raimondo F; Neri A; Morabito F; Musto P; Gentile M
Hematol Oncol; 2024 Jul; 42(4):e3290. PubMed ID: 38818978
[TBL] [Abstract][Full Text] [Related]
2. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials.
Bruzzese A; Derudas D; Galli M; Martino EA; Rocco S; Conticello C; Califano C; Giuliani N; Mangiacavalli S; Farina G; Lombardo A; Brunori M; Rossi E; Antonioli E; Ria R; Zambello R; Di Renzo N; Mele G; Marcacci G; Pietrantuono G; Palumbo G; Cascavilla N; Cerchione C; Belotti A; Criscuolo C; Uccello G; Curci P; Vigna E; Mendicino F; Iaccino E; Mimmi S; Botta C; Vincelli D; Sgherza N; Bonalumi A; Cupelli L; Stocchi R; Martino M; Ballanti S; Gangemi D; Gagliardi A; Gamberi B; Pompa A; Tripepi G; Frigeri F; Consoli U; Bringhen S; Zamagni E; Patriarca F; De Stefano V; Di Raimondo F; Palmieri S; Petrucci MT; Offidani M; Musto P; Boccadoro M; Cavo M; Neri A; Morabito F; Gentile M
Hematol Oncol; 2022 Oct; 40(4):704-715. PubMed ID: 35608183
[TBL] [Abstract][Full Text] [Related]
3. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.
Dimopoulos MA; Lonial S; Betts KA; Chen C; Zichlin ML; Brun A; Signorovitch JE; Makenbaeva D; Mekan S; Sy O; Weisel K; Richardson PG
Cancer; 2018 Oct; 124(20):4032-4043. PubMed ID: 30204239
[TBL] [Abstract][Full Text] [Related]
4. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.
Gentile M; Vigna E; Palmieri S; Galli M; Derudas D; Mina R; Della Pepa R; Zambello R; Martino EA; Bruzzese A; Mangiacavalli S; Zamagni E; Califano C; Musso M; Conticello C; Cerchione C; Mele G; Di Renzo N; Offidani M; Tarantini G; Casaluci GM; Rago A; Ria R; Uccello G; Barilà G; Palumbo G; Pompa A; Vincelli D; Brunori M; Accardi F; Amico V; Amendola A; Fontana R; Bongarzoni V; Rossini B; Cotzia E; Gozzetti A; Rizzi R; Sgherza N; Ferretti E; Bertuglia G; Nappi D; Petrucci MT; Di Raimondo F; Neri A; Morabito F; Musto P
Haematologica; 2024 Jan; 109(1):245-255. PubMed ID: 37439329
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
6. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
Ide T; Osawa M; Sanghavi K; Vezina HE
Cancer Chemother Pharmacol; 2022 Jan; 89(1):129-140. PubMed ID: 34825942
[TBL] [Abstract][Full Text] [Related]
8. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
[TBL] [Abstract][Full Text] [Related]
9. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.
Miguel JS; Weisel K; Moreau P; Lacy M; Song K; Delforge M; Karlin L; Goldschmidt H; Banos A; Oriol A; Alegre A; Chen C; Cavo M; Garderet L; Ivanova V; Martinez-Lopez J; Belch A; Palumbo A; Schey S; Sonneveld P; Yu X; Sternas L; Jacques C; Zaki M; Dimopoulos M
Lancet Oncol; 2013 Oct; 14(11):1055-1066. PubMed ID: 24007748
[TBL] [Abstract][Full Text] [Related]
10. Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centers.
Hose D; Schreder M; Hefner J; Bittrich M; Danhof S; Strifler S; Krauth MT; Schoder R; Gisslinger B; Einsele H; Gisslinger H; Knop S
J Cancer Res Clin Oncol; 2021 Jan; 147(1):205-212. PubMed ID: 32683487
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
[TBL] [Abstract][Full Text] [Related]
12. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
Afifi S; Michael A; Lesokhin A
Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of daratumumab, pomalidomide, and dexamethasone versus daratumumab, carfilzomib, and dexamethasone in daratumumab-naïve relapsed multiple myeloma.
Dima D; Mansour R; Davis JA; Minchak M; Goel U; Atallah R; Logan E; Tabak C; Rashid A; Ahmed N; Abdallah AO; Hashmi H
Eur J Haematol; 2024 Jun; 112(6):975-983. PubMed ID: 38382632
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
18. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma.
Abdallah AO; Mohyuddin GR; Mahmoudjafari Z; Atrash S; Kawsar H; Sigle M; Shune L; McGuirk J; Ganguly S
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e212-e219. PubMed ID: 33051166
[TBL] [Abstract][Full Text] [Related]
20. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study.
Kelly KR; Ailawadhi S; Siegel DS; Heffner LT; Somlo G; Jagannath S; Zimmerman TM; Munshi NC; Madan S; Chanan-Khan A; Lonial S; Chandwani S; Minasyan A; Ruehle M; Barmaki-Rad F; Abdolzade-Bavil A; Rharbaoui F; Herrmann-Keiner E; Haeder T; Wartenberg-Demand A; Anderson KC
Lancet Haematol; 2021 Nov; 8(11):e794-e807. PubMed ID: 34529955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
